论文部分内容阅读
目的观察中药、干扰素联合化疗药治疗晚期非小细胞肺癌(NSCLC)的临床效果。方法将200例晚期NSCLC患者随机分为研究组和对照组各100例。对照组采用干扰素联合化疗治疗,研究组在对照组的基础上加用中药治疗。对比2组临床疗效、中医症候改善情况及不良反应发生情况。结果研究组治疗总有效率为80.0%高于对照组的59.0%,差异有统计学意义(P<0.05)。研究组中医症候改善的总有效率为82.0%明显高于对照组的70.0%,差异具有统计学意义(P<0.05)。研究组消化道反应、骨髓抑制及神经毒性发生率明显少于对照组,差异有统计学意义(P<0.05)。结论中药结合干扰素联合化疗对NSCLC进行治疗,疗效较好,不良反应较少、安全性较高,具有较高临床价值。
Objective To observe the clinical effects of traditional Chinese medicine and interferon combined with chemotherapeutic drugs in the treatment of advanced non-small cell lung cancer (NSCLC). Methods 200 patients with advanced NSCLC were randomly divided into study group and control group of 100 cases. Control group with interferon combined with chemotherapy, the study group in the control group based on the use of traditional Chinese medicine. Compare the clinical curative effect of 2 groups, the improvement of TCM symptoms and the occurrence of adverse reactions. Results The total effective rate of the study group was 80.0% higher than that of the control group (59.0%), the difference was statistically significant (P <0.05). The total effective rate of TCM symptom improvement in study group was 82.0%, which was significantly higher than that in control group (70.0%), the difference was statistically significant (P <0.05). The incidence of digestive tract reaction, bone marrow suppression and neurotoxicity in the study group was significantly less than that in the control group, with significant difference (P <0.05). Conclusion Chinese medicine combined with interferon combined with chemotherapy for the treatment of NSCLC, the effect is better, fewer adverse reactions, higher safety, with high clinical value.